{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:29:17Z","timestamp":1786681757273,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05412-3","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:45:53Z","timestamp":1781077553000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The influence of the secretome from human amniotic mesenchymal stem cells on p53 and MDM2 expression in MDA-MB-231 breast cancer cell line"],"prefix":"10.1007","volume":"17","author":[{"given":"Rezvan","family":"Asadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Safari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"3","key":"5412_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"5412_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000520370","volume":"212","author":"T Shakery","year":"2023","unstructured":"Shakery T, Safari F. Downregulation of Pinkbar\/pAKT and MMP2\/MMP9 Expression in MDA-MB-231 Breast Cancer Cells as Potential Targets in Cancer Therapy by hAMSCs Secretome. Cells Tissues Organs. 2023;212(2):155\u201363. https:\/\/doi.org\/10.1159\/000520370.","journal-title":"Cells Tissues Organs"},{"issue":"6","key":"5412_CR3","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1007\/s12094-022-03067-4","volume":"25","author":"M Rahimi Lifshagerd","year":"2023","unstructured":"Rahimi Lifshagerd M, Safari F. Therapeutic effects of hAMSCs secretome on proliferation of MDA-MB-231 breast cancer cells by the cell cycle arrest in G1\/S phase, Clin. Transl Oncol. 2023;25(6):1702\u20139. https:\/\/doi.org\/10.1007\/s12094-022-03067-4.","journal-title":"Transl Oncol"},{"key":"5412_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.addr.2014.10.007","volume":"82\u201383","author":"C Tran","year":"2015","unstructured":"Tran C, Damaser MS. Stem cells as drug delivery methods: application of stem cell secretome for regeneration. AdvDrug Deliv Rev. 2015;82\u201383:1\u201311. https:\/\/doi.org\/10.1016\/j.addr.2014.10.007.","journal-title":"AdvDrug Deliv Rev"},{"issue":"3","key":"5412_CR5","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/jcp.21068","volume":"212","author":"GE Kilroy","year":"2007","unstructured":"Kilroy GE, Foster SJ, Wu X, Ruiz J, Sherwood S, Heifetz A, Ludlow JW, Stricker DM, Potiny S, Green P, Halvorsen YD, Cheatham B, Storms RW, Gimble JM. Cytokine profile of human adiposederived stem cells: expression of angiogenic, hematopoietic, and proinflammatory factors. J Cell Physiol. 2007;212(3):702\u20139. https:\/\/doi.org\/10.1002\/jcp.21068.","journal-title":"J Cell Physiol"},{"key":"5412_CR6","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/path.2469","volume":"217","author":"AI Caplan","year":"2009","unstructured":"Caplan AI. Why are MSCs therapeutic? New data: new insight. J Pathol. 2009;217:318\u201324. https:\/\/doi.org\/10.1002\/path.2469.","journal-title":"J Pathol"},{"issue":"5","key":"5412_CR7","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/jcb.21748","volume":"104","author":"H Sarojini","year":"2008","unstructured":"Sarojini H, Estrada R, Lu H, Dekova S, Lee MJ, Gray RD, Wang E. PEDF from mouse mesenchymal stem cell secretome attracts fibroblasts. J Cell Biochem. 2008;104(5):1793\u2013802. https:\/\/doi.org\/10.1002\/jcb.21748.","journal-title":"J Cell Biochem"},{"key":"5412_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1089\/scd.2007.0175","volume":"17","author":"T Schinkothe","year":"2008","unstructured":"Schinkothe T, Bloch W, Schmidt A. In vitro secreting profile of human mesenchymal stem cells. Stem Cells Dev. 2008;17:199\u2013206. https:\/\/doi.org\/10.1089\/scd.2007.0175.","journal-title":"Stem Cells Dev"},{"issue":"Pt 1","key":"5412_CR9","doi-asserted-by":"publisher","first-page":"113265","DOI":"10.1016\/j.intimp.2024.113265","volume":"143","author":"M Rasouli","year":"2024","unstructured":"Rasouli M, Alavi M, D\u2019Angelo A, Sobhani N, Roudi R, Safari F. Exploring the dichotomy of the mesenchymal stem cell secretome: Implications for tumor modulation via cell-signaling pathways. Int Immunopharmacol. 2024;143(Pt 1):113265. https:\/\/doi.org\/10.1016\/j.intimp.2024.113265.","journal-title":"Int Immunopharmacol"},{"key":"5412_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1158\/1541-7786.MCR-07-0239","volume":"6","author":"A Forslund","year":"2008","unstructured":"Forslund A, Zeng Z, Qin LX, Rosenberg S, Ndubuisi M, Pincas H, et al. MDM2 gene amplification is correlated to tumor progression but not to the presence of SNP309 or TP53 mutational status in primary colorectal cancers. Mol Cancer Res. 2008;6:205\u201311. https:\/\/doi.org\/10.1158\/1541-7786.MCR-07-0239.","journal-title":"Mol Cancer Res"},{"key":"5412_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1746-1596-9-71","volume":"9","author":"Q Yu","year":"2014","unstructured":"Yu Q, Li Y, Mu K, Li Z, Meng Q, Wu X, et al. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations. Diagn Pathol. 2014;9:71. https:\/\/doi.org\/10.1186\/1746-1596-9-71.","journal-title":"Diagn Pathol"},{"key":"5412_CR12","doi-asserted-by":"publisher","first-page":"393416","DOI":"10.2174\/1381612003400911","volume":"6","author":"H Zhang, Wang","year":"2000","unstructured":"Zhang, Wang H. MDM2 oncogene as a novel target for human cancer therapy. Curr Pharm Des. 2000;6:393416. https:\/\/doi.org\/10.2174\/1381612003400911.","journal-title":"Curr Pharm Des"},{"key":"5412_CR13","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrc2723","volume":"9","author":"AJ Levine","year":"2009","unstructured":"Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009;9:749\u201358. https:\/\/doi.org\/10.1038\/nrc2723.","journal-title":"Nat Rev Cancer"},{"key":"5412_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2174\/1568009053332636","volume":"5","author":"E Rayburn","year":"2005","unstructured":"Rayburn E, Zhang R, He J, Wang H. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets. 2005;5:27\u201341. https:\/\/doi.org\/10.2174\/1568009053332636.","journal-title":"Curr Cancer Drug Targets"},{"key":"5412_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1177\/1947601912454734","volume":"3","author":"W Hu","year":"2012","unstructured":"Hu W, Feng Z, Levine AJ. The Regulation of Multiple p53 Stress Responses is Mediated through MDM2. Genes Cancer. 2012;3:199\u2013208. https:\/\/doi.org\/10.1177\/1947601912454734.","journal-title":"Genes Cancer"},{"key":"5412_CR16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/s1097-2765(01)00214-3","volume":"7","author":"K Nakano","year":"2001","unstructured":"Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell. 2001;7:683\u201394. https:\/\/doi.org\/10.1016\/s1097-2765(01)00214-3.","journal-title":"Mol Cell"},{"key":"5412_CR17","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/s1097-2765(01)00213-1","volume":"7","author":"J Yu","year":"2001","unstructured":"Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell. 2001;7:673\u201382. https:\/\/doi.org\/10.1016\/s1097-2765(01)00213-1.","journal-title":"Mol Cell"},{"key":"5412_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-60761-416-6_1","volume":"596","author":"BC Baguley","year":"2010","unstructured":"Baguley BC. Multidrug resistance in cancer. Methods Mol Biol. 2010;596:1\u201314. https:\/\/doi.org\/10.1007\/978-1-60761-416-6_1.","journal-title":"Methods Mol Biol"},{"key":"5412_CR19","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/nrc864","volume":"2","author":"KH Vousden","year":"2002","unstructured":"Vousden KH, Lu X. Live of let die: The cell\u2019s response to p53. Nat Rev Cancer. 2002;2:594\u2013604. https:\/\/doi.org\/10.1038\/nrc864.","journal-title":"Nat Rev Cancer"},{"key":"5412_CR20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1677\/erc.1.01172","volume":"13","author":"M Lacroix","year":"2006","unstructured":"Lacroix M, Toillon RA, Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer. 2006;13:293\u2013325. https:\/\/doi.org\/10.1677\/erc.1.01172.","journal-title":"Endocr Relat Cancer"},{"key":"5412_CR21","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","volume":"29","author":"K Engeland","year":"2022","unstructured":"Engeland K. Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 2022;29:946\u201360. https:\/\/doi.org\/10.1038\/s41418-022-00988-z.","journal-title":"Cell Death Differ"},{"key":"5412_CR22","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1038\/onc.2016.502","volume":"36","author":"M Fischer","year":"2017","unstructured":"Fischer M. Census and evaluation of p53 target genes. Oncogene. 2017;36:3943\u201356. https:\/\/doi.org\/10.1038\/onc.2016.502.","journal-title":"Oncogene"},{"issue":"6","key":"5412_CR23","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/cbf.3654","volume":"39","author":"F Safari","year":"2021","unstructured":"Safari F, Shakery T, Sayadamin N. Evaluating the effect of secretome of human amniotic mesenchymal stromal cells on apoptosis induction and epithelial- mesenchymal transition inhibition in LNCaP prostate cancer cells based on 2D and 3D cell culture models. Cell Biochem Funct. 2021;39(6):813\u201320. https:\/\/doi.org\/10.1002\/cbf.3654.","journal-title":"Cell Biochem Funct"},{"key":"5412_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/030089169608200303","volume":"82","author":"V Chiarugi","year":"1996","unstructured":"Chiarugi V, Ruggiero M. Role of three cancer \u2018master genes\u2019 p53, bcl2 and c-myc on the apoptotic process. Tumori. 1996;82:205\u20139.","journal-title":"Tumori"},{"key":"5412_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.surg.2013.03.012","volume":"154","author":"S Huerta","year":"2013","unstructured":"Huerta S, Gao X, Dineen S, Kapur P, Saha D, Meyer J. Role of p53, Bax, p21, and DNA-PKcs in radiation sensitivity of HCT-116 cells and xenografts. Surgery. 2013;154:143\u201351. https:\/\/doi.org\/10.1016\/j.surg.2013.03.012.","journal-title":"Surgery"},{"issue":"3","key":"5412_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/jso.21819","volume":"103","author":"SY Jung","year":"2011","unstructured":"Jung SY, Jeong J, Shin SH, Kwon Y, Kim EA, Ko KL, Shin KH, Ro J, Lee KS, Park IH, Lee S, Kim SW, Kang HS. Accumulation of p53 determined by immunohistochemistry as a prognostic marker in node negative breast cancer; analysis according to St Gallen consensus and intrinsic subtypes. J Surg Oncol. 2011;103(3):207\u201311. https:\/\/doi.org\/10.1002\/jso.21819.","journal-title":"J Surg Oncol"},{"issue":"4","key":"5412_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/BF01606889","volume":"423","author":"M Koshiyama","year":"1993","unstructured":"Koshiyama M, Konishi I, Wang DP, Mandai M, Komatsu T, Yamamoto S, Nanbu K, Naito MF, Mori T. Immunohistochemical analysis of p53 protein over-expression in endometrial carcinomas: inverse correlation with sex steroid receptor status. Virchows Arch Pathol Anat Histopathol. 1993;423(4):265\u201371. https:\/\/doi.org\/10.1007\/BF01606889.","journal-title":"Virchows Arch Pathol Anat Histopathol"},{"issue":"4","key":"5412_CR28","doi-asserted-by":"publisher","first-page":"488","DOI":"10.4103\/0974-7796.158507","volume":"7","author":"R Verma","year":"2015","unstructured":"Verma R, Gupta V, Singh J, Verma M, Gupta G, Gupta S, Sen R, Ralli M. Significance of p53 and ki-67 expression in prostate cancer. Urol Ann. 2015;7(4):488\u201393. https:\/\/doi.org\/10.4103\/0974-7796.158507.","journal-title":"Urol Ann"},{"issue":"4","key":"5412_CR29","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.3892\/ol.2014.2343","volume":"8","author":"K Huang","year":"2014","unstructured":"Huang K, Chen L, Zhang J, Wu Z, Lan L, Wang L, Lu B, Liu Y. Elevated p53 expression levels correlate with tumor progression and poor prognosis in patients exhibiting esophageal squamous cell carcinoma. Oncol Lett. 2014;8(4):1441\u20136. https:\/\/doi.org\/10.3892\/ol.2014.2343.","journal-title":"Oncol Lett"},{"key":"5412_CR30","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1093\/nar\/26.15.3453","volume":"26","author":"J Momand","year":"1998","unstructured":"Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 1998;26:3453\u20139. https:\/\/doi.org\/10.1093\/nar\/26.15.3453.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"5412_CR31","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00438-023-02043-z","volume":"298","author":"A Parvez","year":"2023","unstructured":"Parvez A, Mahjabeen I, Mehmood A, Khan AU, Nisar A, Kayani MA. Expression variations of DNA damage response genes ATM and ATR in blood cancer patients. Mol Genet Genomics. 2023;298(5):1173\u201383. https:\/\/doi.org\/10.1007\/s00438-023-02043-z.","journal-title":"Mol Genet Genomics"},{"key":"5412_CR32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.bbacli.2014.08.001","volume":"2","author":"TM Abdel-Fatah","year":"2014","unstructured":"Abdel-Fatah TM, Arora A, Moseley P, Coveney C, Perry C, Johnson K, Kent C, Ball G, Chan S, Madhusudan S. ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers. BBA Clin. 2014;2:10\u20137. https:\/\/doi.org\/10.1016\/j.bbacli.2014.08.001.","journal-title":"BBA Clin"},{"issue":"9","key":"5412_CR33","first-page":"1571","volume":"2","author":"AA Elbendary","year":"1996","unstructured":"Elbendary AA, Cirisano FD, Evans AC Jr, Davis PL, Iglehart JD, Marks JR, Berchuck A. Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells. Clin Cancer Res. 1996;2(9):1571\u20135.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"5412_CR34","doi-asserted-by":"publisher","first-page":"6257","DOI":"10.1158\/0008-5472.CAN-18-0338","volume":"78","author":"S Jeay","year":"2018","unstructured":"Jeay S, Ferretti S, Holzer P, Fuchs J, Chapeau EA, Wartmann M, Sterker D, Romanet V, Murakami M, Kerr G, Durand EY, Gaulis S, Cortes-Cros M, Ruetz S, Stachyra TM, Kallen J, Furet P, W\u00fcrthner J, Guerreiro N, Halilovic E, Jullion A, Kauffmann A, Kuriakose E, Wiesmann M, Jensen MR, Hofmann F, Sellers WR. Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201. Cancer Res. 2018;78(21):6257\u201367. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-0338.","journal-title":"Cancer Res"},{"key":"5412_CR35","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1158\/1078-0432.CCR-17-2730","volume":"25","author":"A Andrews","year":"2019","unstructured":"Andrews A, Warner K, Rodriguez-Ramirez C, Pearson AT, Nor F, Zhang Z, Kerk S, Kulkarni A, Helman JI, Brenner JC, et al. Ablation of cancer stem cells by therapeutic inhibition of the MDM2\u2013p53 interaction in mucoepidermoid carcinoma. Clin Cancer Res. 2019;25:1588\u2013600. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2730.","journal-title":"Clin Cancer Res"},{"key":"5412_CR36","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1089\/cbr.2018.2732","volume":"34","author":"A Al-Ghabkari","year":"2019","unstructured":"Al-Ghabkari A, Narendran A. In Vitro Characterization of a Potent p53-MDM2 Inhibitor, RG7112 in Neuroblastoma Cancer Cell Lines. Cancer Biother Radiopharm. 2019;34:252\u20137. https:\/\/doi.org\/10.1089\/cbr.2018.2732.","journal-title":"Cancer Biother Radiopharm"},{"key":"5412_CR37","doi-asserted-by":"publisher","first-page":"13275","DOI":"10.3390\/ijms150813275","volume":"15","author":"X Ji","year":"2014","unstructured":"Ji X, Huang Q, Yu L, Nussinov R, Ma B. Bioinformatics Study of Cancer-Related Mutations within p53 Phosphorylation Site Motifs. Int J Mol Sci. 2014;15:13275\u201398. https:\/\/doi.org\/10.3390\/ijms150813275.","journal-title":"Int J Mol Sci"},{"key":"5412_CR38","doi-asserted-by":"publisher","unstructured":"Cai X, Liu X. Inhibition of Thr-55 phosphorylation restores p53 nuclear localization and sensitizes cancer cells to DNA damage. Proc Natl Acad Sci U S A. 2008; 105(44): 16958\u201363. https:\/\/doi.org\/10.1073\/pnas.0804608105","DOI":"10.1073\/pnas.0804608105"},{"issue":"6","key":"5412_CR39","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/j.1582-4934.2007.00150.x","volume":"11","author":"RA Lockshin","year":"2007","unstructured":"Lockshin RA, Zakeri Z. Cell death in health and disease. J Cell Mol Med. 2007;11(6):1214\u201324. https:\/\/doi.org\/10.1111\/j.1582-4934.2007.00150.x.","journal-title":"J Cell Mol Med"},{"issue":"3","key":"5412_CR40","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/ijc.24064","volume":"124","author":"S Fulda","year":"2009","unstructured":"Fulda S. Tumor resistance to apoptosis. Int J Cancer. 2009;124(3):511\u20135. https:\/\/doi.org\/10.1002\/ijc.24064.","journal-title":"Int J Cancer"},{"key":"5412_CR41","doi-asserted-by":"publisher","first-page":"101479","DOI":"10.1016\/j.tice.2020.101479","volume":"68","author":"Z Rahmani","year":"2021","unstructured":"Rahmani Z, Safari F. Evaluating the in vitro therapeutic effects of human amniotic mesenchymal stromal cells on MiaPaca2 pancreatic cancer cells using 2D and 3D cell culture model. Tissue Cell. 2021;68:101479. doi.org\/10.1016\/j. tice.2020.101479.","journal-title":"Tissue Cell"},{"key":"5412_CR42","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.biologicals.2022.02.001","volume":"76","author":"M Alidoust Saharkhiz Lahiji","year":"2022","unstructured":"Alidoust Saharkhiz Lahiji M, Safari F. Potential therapeutic effects of hAMSCs secretome on Panc1 pancreatic cancer cells through downregulation of SgK269, E- cadherin, vimentin, and snail expression. Biologicals. 2022;76:24\u201330. https:\/\/doi.org\/10.1016\/j.biologicals.2022.02.001.","journal-title":"Biologicals"},{"issue":"2","key":"5412_CR43","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s12013-022-01066-4","volume":"80","author":"S Ebadi Zavieh","year":"2022","unstructured":"Ebadi Zavieh S, Safari F. The Antitumor Activity of hAMSCs Secretome in HT-29 Colon Cancer Cells Through Downregulation of EGFR\/c-Src\/IRTKS Expression and p38\/ERK1\/2 Phosphorylation, Cell Biochem. Biophys. 2022;80(2):395\u2013402. https:\/\/doi.org\/10.1007\/s12013-022-01066-4.","journal-title":"Biophys"},{"key":"5412_CR44","doi-asserted-by":"publisher","first-page":"102160","DOI":"10.1016\/j.tice.2023.102160","volume":"84","author":"F Safari","year":"2023","unstructured":"Safari F, Dadvar F. In vitro evaluation of autophagy and cell death induction in Panc1 pancreatic cancer by secretome of hAMSCs through downregulation of p-AKT\/p-mTOR and upregulation of p-AMPK\/ULK1 signal transduction pathways. Tissue Cell. 2023;84:102160. https:\/\/doi.org\/10.1016\/j.tice.2023.102160.","journal-title":"Tissue Cell"},{"key":"5412_CR45","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12935-015-0198-9","volume":"15","author":"D Chen","year":"2015","unstructured":"Chen D, Liu S, Ma H, Liang X, Ma H, Yan X, Yang B, Wei J, Liu X. Paracrine factors from adiposemesenchymal stem cells enhance metastatic capacity through Wnt signaling pathway in a colon cancer cell co-culture model. Cancer Cell Int. 2015;15:42. https:\/\/doi.org\/10.1186\/s12935-015-0198-9.","journal-title":"Cancer Cell Int"},{"key":"5412_CR46","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3892\/ijo.2015.3122","volume":"47","author":"KA So","year":"2015","unstructured":"So KA, Min KJ, Hong JH, Lee JK. Interleukin-6 expression by interactions between gynecologic cancer cells and human mesenchymal stem cells promotes epithelial-mesenchymal transition. Int J Oncol. 2015;47:1451\u20139. https:\/\/doi.org\/10.3892\/ijo.2015.3122.","journal-title":"Int J Oncol"},{"key":"5412_CR47","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.3727\/096368915X687462","volume":"24","author":"F Ma","year":"2015","unstructured":"Ma F, Chen D, Chen F, Chi Y, Han Z, Feng X, Li X, Han Z. Human umbilical cord mesenchymal stem cells promote breast cancer metastasis by interleukin-8- and interleukin-6-dependent induction of CD44+\/CD24\u2009\u2013\u2009Cells. Cell Transplant. 2015;24:2585\u201399. https:\/\/doi.org\/10.3727\/096368915X687462.","journal-title":"Cell Transplant"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05412-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05412-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05412-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:06:20Z","timestamp":1786680380000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05412-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5412"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05412-3","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1184"}}